脑脊液生物标志物检测在阿尔茨海默病诊断中值得注意的若干问题

Cerebrospinal fluid examination in the diagnosis of Alzheimer's disease on several issues worthy of attention

生物标志物检测在阿尔茨海默病诊断中至关重要,其中脑脊液生物标志物检测因其高度的敏感性、特异性和可操作性,在临床上较示踪剂正电子发射计算机断层显像(positron emissiontomography,PET)更易普及。但目前国内医院脑脊液生物标志物检测大多依赖于院外的检测机构,且无统一的检测规范和标准,常导致检测结果误差较大,因此本文就脑脊液生物标志物检测过程中值得注意的若干问题作一概述,以期最大限度的缩小脑脊液生物标志物在临床检测中的误差,充分发挥其在AD早期诊断中的重要价值。

Detection of biomarkers is crucial in the diagnosis of Alzheimer’s disease, in which the examination of cerebrospinal fluid biomarkers is easier to be carried out than the tracer PET in clinical practice because of its high sensitivity, specificity and operability. However,at present, the domestic cerebrospinal fluid biomarkers testing is mostly affected by out-of-hospital testing institutions, and there is no unified detection criterion and standard,, resulting in large testing errors. Therefore, this article summarizes several noteworthy issues in the collection and detection of cerebrospinal fluid in order to minimize the error in the clinical detection of cerebrospinal fluid biomarkers and give full play to the important value of cerebrospinal fluid biomarkers examination in the early diagnosis of AD.